Logo image of BCEL

ATRECA INC - A (BCEL) Stock Fundamental Analysis

NASDAQ:BCEL - Nasdaq - US04965G1094 - Common Stock - Currency: USD

0.15  -0.02 (-11.76%)

After market: 0.1399 -0.01 (-6.73%)

Fundamental Rating

2

Overall BCEL gets a fundamental rating of 2 out of 10. We evaluated BCEL against 557 industry peers in the Biotechnology industry. BCEL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCEL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BCEL has reported negative net income.
In the past year BCEL has reported a negative cash flow from operations.
In the past 5 years BCEL always reported negative net income.
In the past 5 years BCEL always reported negative operating cash flow.
BCEL Yearly Net Income VS EBIT VS OCF VS FCFBCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -371.75%, BCEL is doing worse than 97.11% of the companies in the same industry.
Looking at the Return On Equity, with a value of -905.28%, BCEL is doing worse than 85.03% of the companies in the same industry.
Industry RankSector Rank
ROA -371.75%
ROE -905.28%
ROIC N/A
ROA(3y)-49.68%
ROA(5y)-42.94%
ROE(3y)-76.72%
ROE(5y)-59.76%
ROIC(3y)N/A
ROIC(5y)N/A
BCEL Yearly ROA, ROE, ROICBCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCEL Yearly Profit, Operating, Gross MarginsBCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, BCEL has more shares outstanding
BCEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCEL Yearly Shares OutstandingBCEL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M
BCEL Yearly Total Debt VS Total AssetsBCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

BCEL has an Altman-Z score of -37.58. This is a bad value and indicates that BCEL is not financially healthy and even has some risk of bankruptcy.
BCEL has a worse Altman-Z score (-37.58) than 93.71% of its industry peers.
There is no outstanding debt for BCEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.58
ROIC/WACCN/A
WACCN/A
BCEL Yearly LT Debt VS Equity VS FCFBCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

BCEL has a Current Ratio of 1.58. This is a normal value and indicates that BCEL is financially healthy and should not expect problems in meeting its short term obligations.
BCEL has a worse Current ratio (1.58) than 83.50% of its industry peers.
BCEL has a Quick Ratio of 1.58. This is a normal value and indicates that BCEL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.58, BCEL is doing worse than 81.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.58
BCEL Yearly Current Assets VS Current LiabilitesBCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.35% over the past year.
EPS 1Y (TTM)29.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BCEL will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.29% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.77%
EPS Next 2Y28.42%
EPS Next 3Y18.1%
EPS Next 5Y9.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCEL Yearly Revenue VS EstimatesBCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2028 2M 4M 6M 8M 10M
BCEL Yearly EPS VS EstimatesBCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCEL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCEL Price Earnings VS Forward Price EarningsBCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCEL Per share dataBCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

BCEL's earnings are expected to grow with 18.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.42%
EPS Next 3Y18.1%

More info and screens

0

5. Dividend

5.1 Amount

BCEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATRECA INC - A

NASDAQ:BCEL (3/18/2024, 8:00:01 PM)

After market: 0.1399 -0.01 (-6.73%)

0.15

-0.02 (-11.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2024-03-13/amc
Earnings (Next)05-08 2024-05-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners11.24%
Ins Owner Change0%
Market Cap5.94M
Analysts82
Price Target5.61 (3640%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.92%
Min EPS beat(2)0.5%
Max EPS beat(2)15.33%
EPS beat(4)4
Avg EPS beat(4)8.36%
Min EPS beat(4)0.5%
Max EPS beat(4)15.33%
EPS beat(8)7
Avg EPS beat(8)8.6%
EPS beat(12)9
Avg EPS beat(12)5.63%
EPS beat(16)11
Avg EPS beat(16)3.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)69.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.89%
EPS NY rev (1m)-204.48%
EPS NY rev (3m)-4.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -371.75%
ROE -905.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.68%
ROA(5y)-42.94%
ROE(3y)-76.72%
ROE(5y)-59.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.58
Altman-Z -37.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)332.95%
Cap/Depr(5y)265.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35%
EPS Next Y16.77%
EPS Next 2Y28.42%
EPS Next 3Y18.1%
EPS Next 5Y9.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.79%
EBIT Next 3Y6.88%
EBIT Next 5Y-0.01%
FCF growth 1Y31.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.43%
OCF growth 3YN/A
OCF growth 5YN/A